NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Son, Sung Wook | - |
dc.contributor.author | Cho, Eunho | - |
dc.contributor.author | Cho, Hanbyoul | - |
dc.contributor.author | Woo, Seon Rang | - |
dc.contributor.author | Lee, Hyo-Jung | - |
dc.contributor.author | Oh, Se Jin | - |
dc.contributor.author | Kim, Suyeon | - |
dc.contributor.author | Kim, Jae-Hoon | - |
dc.contributor.author | Chung, Eun Joo | - |
dc.contributor.author | Chung, Joon-Yong | - |
dc.contributor.author | Kim, Min Gyu | - |
dc.contributor.author | Song, Kwon-Ho | - |
dc.contributor.author | Kim, Tae Woo | - |
dc.date.accessioned | 2022-08-13T16:40:18Z | - |
dc.date.available | 2022-08-13T16:40:18Z | - |
dc.date.created | 2022-08-12 | - |
dc.date.issued | 2022-05-23 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/143049 | - |
dc.description.abstract | Cancer immunoediting drives the adaptation of tumor cells to host immune surveillance. Previously, we have demonstrated that immunoediting driven by cytotoxic T lymphocytes (CTLs) enriches NANOG(+) tumor cells with immune-refractory properties. Here, we found that CTL-mediated immune pressure triggered cross-resistance of tumor cells to the complement system, a part of the innate immune system. In this process, NANOG upregulated the membrane-bound complement regulatory protein (mCRP) CD59 through promoter occupancy, thereby contributing to the resistance of tumor cells against complement-dependent cytotoxicity (CDC). Notably, targeting of NANOG sensitized the immune-refractory tumor cells to trastuzumab-mediated CDC. Collectively, our results revealed a possible mechanism through which selection imposed by T-cell based immunotherapy triggered complement-resistant phenotypes in the tumor microenvironment (TME), by establishing a firm molecular link between NANOG and CD59 in immune-edited tumor cells. We believe these results hold important implications for the clinical application of CDC-mediated therapeutic antibody. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE PORTFOLIO | - |
dc.subject | IN-VITRO | - |
dc.subject | CANCER | - |
dc.subject | ANTIBODIES | - |
dc.subject | IMMUNOTHERAPY | - |
dc.subject | TRASTUZUMAB | - |
dc.subject | EXPRESSION | - |
dc.title | NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Tae Woo | - |
dc.identifier.doi | 10.1038/s41598-022-12692-6 | - |
dc.identifier.scopusid | 2-s2.0-85130417468 | - |
dc.identifier.wosid | 000799388600018 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, v.12, no.1 | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.citation.title | SCIENTIFIC REPORTS | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | ANTIBODIES | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | TRASTUZUMAB | - |
dc.subject.keywordPlus | EXPRESSION | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.